Siponimod Medicine 09 January 2018 Extended indication Secundair progressieve multiple sclerose (SPMS) en relapsing remitting multiple sclerose (RRMS). Therapeutic value No judgement Total cost Registration phase Clinical trials Product Active substance Siponimod Domain Neurological disorders Reason of inclusion Main indication Multiple sclerosis Extended indication Secundair progressieve multiple sclerose (SPMS) en relapsing remitting multiple sclerose (RRMS). Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Novartis Portfolio holder Mechanism of action Unknown Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Selectieve remmer van de Sphingosine Phosphate Receptor. Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity New medicine ATMP Unknown Submission date Expected Registration 2019 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Fingolimod en andere MS middelen. Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Hersenstichting, Nationaal MS fonds. Additional remarks Hersenstichting: In Nederland komt MS voor bij ongeveer 1 op de 1000 inwoners. Nederland telt dus ongeveer 17.000 mensen met MS. Ongeveer 40% van alle mensen met MS heeft de Secundair Progressieve MS variant en 40% van de mensen met MS met RRMS (samen 13600 personen). Net als de andere middelen voor (RR)MS in deze horizonscan zal ook dit middel afhankelijk van de meerwaarde ten opzichte van de huidige behandelopties bij een wat kleiner of groter deel van deze totale patiëntenpopulatie worden ingezet. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks